Description

GSK-LSD1, an LSD1 inhibitor, decreases food consumption and body weight while enhancing insulin sensitivity and glycemic regulation in murine obesity models. Additionally, it mitigates non-alcoholic fatty liver disease (NAFLD) and suppresses cytokine release induced by SARS-CoV-2 in COVID-19 peripheral blood mononuclear cells (PBMCs). Furthermore, GSK-LSD1 inhibits the proliferation and spread of cancer.

For research use only. We do not sell to patients.

Specification

CAS Number	1431368-48-7
Molecular Weight	289.24
PubChem Substance ID	329825454
Purity	≥98%
form	powder
color	white to beige
solubility	H2O: 20 mg/mL, clear
storage temp.	2-8°C
SMILES string	C1(N[C@@H]2C[C@H]2C3=CC=CC=C3)CCNCC1
InChI	1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1
InChI key	BASFYRLYJAZPPL-UONOGXRCSA-N

Disclaimer: For laboratory research use only.